Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 Tablets in Adult Patients With Alopecia Areata

NCT04346316 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.

NCT NCT04346316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04346316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind and Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SHR0302 Tablets in Adult Patients With Alopecia Areata
Lead sponsor
Reistone Biopharma Company Limited
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2020
Completion date
June 29, 2021
Enrollment
94 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata